What Level 2 Clinical Affairs Maturity Looks Like in Medical Device Organizations

You have CER templates. Your literature search protocol references PubMed and Embase. The CERs follow MEDDEV 2.7/1 Rev 4 structure. So why did the notified body reject your CER for the third time — and why does each round of questions take three months to resolve?

This is the Level 2 plateau. The procedures are in place. The templates exist. The quality management system includes a clinical evaluation SOP that was approved eighteen months ago. And yet the clinical evaluation reports that emerge from this documented process keep failing to satisfy the reviewers who matter most.

The answer is that structure is not substance. Level 2 organizations have solved the organizational problem — they have procedures, templates, assigned responsibilities, and scheduled activities. They have not solved the analytical problem. Their CERs follow the right format and contain the wrong depth.

The Anatomy of a Level 2 CER

Open a Level 2 CER to Section 8 — the literature review results. You will find a table listing identified publications with columns for author, year, study design, sample size, and key findings. The studies are categorized as favorable, neutral, or unfavorable. A summary paragraph below the table notes that the majority of identified literature supports the safety and performance of the device.

What you will not find is critical appraisal. No assessment of individual study methodological quality. No evaluation of risk of bias using a recognized framework. No weighting of evidence by quality and relevance. No analysis of why the two unfavorable studies reached different conclusions than the twelve favorable ones — whether the difference reflects patient population, study design, follow-up duration, or endpoint definition. The literature is catalogued. It is not evaluated.

This is the core deficit that notified body reviewers identify, and it is the reason deficiency letters keep arriving. MDCG 2020-13 expects clinical evaluators to critically appraise each piece of clinical data, assess the relevance and weight of each data set, and synthesize the totality of evidence into a reasoned benefit-risk conclusion. A tabulated literature summary — no matter how thoroughly it documents the search methodology that found it — does not meet this standard.

Level 2 Tells

Certain patterns reliably distinguish Level 2 from both Level 1 (which lacks procedures) and Level 3 (which has analytical depth). These tells are observable in the work product and in organizational behavior.

Equivalence tables without clinical reasoning. The CER contains a three-column equivalence comparison — technical, biological, clinical — for each characteristic. Cells are marked with checkmarks or brief statements of similarity. But the table does not address differences, does not analyze whether differences affect clinical safety or performance conclusions, and does not explain why the claimed equivalent device is appropriate when Article 61(5) restrictions make equivalence harder to sustain.

PMCF plans that describe methods but produce no data. The PMCF plan reads well. It identifies literature monitoring, a survey study, and registry participation as planned activities. It has a timeline. It references Annex XIV Part B. Eighteen months after approval, the literature monitoring is running intermittently, the survey study has not been designed, and registry participation has not been initiated. The plan is a document. It is not a program.

CER review cycles measured in quarters. When a CER goes through internal review, the reviewer returns it with substantial comments — not formatting corrections, but requests for deeper analysis, stronger benefit-risk argumentation, and more rigorous literature appraisal. The author makes revisions that partially address the comments. The document circulates again. Three months pass. Then the notified body review adds another cycle. Level 2 CERs take a long time not because they are thorough, but because each review reveals analytical gaps that require rework.

Evaluators who meet criteria on paper. CVs are on file. The evaluator has a relevant degree and sufficient years of experience. But the CER reads as if it were written by someone summarizing the literature for the first time rather than someone who works in the relevant clinical domain. The evaluator qualification process checks credentials without assessing whether the evaluator can produce the analytical depth that MDCG 2020-13 requires.

Why Organizations Stall at Level 2

Level 2 is comfortable. The procedures provide a sense of compliance. The templates provide a sense of completeness. Management sees approved SOPs and completed CERs and concludes that clinical affairs is functioning. The deficiency letters from the notified body are treated as individual document issues — this CER needs more detail here, that CER needs a stronger equivalence argument there — rather than as symptoms of a systemic analytical gap.

The investment required to move from Level 2 to Level 3 is not primarily financial. It is conceptual. The organization must stop thinking about CERs as documents to be produced and start thinking about clinical evidence as a strategic asset to be planned, generated, appraised, and maintained. That shift changes who does the work, how the work is evaluated, and why the work matters.

It means hiring or developing clinical evaluators with genuine therapeutic area expertise, not generalists who can follow a template. It means creating product-level clinical evidence strategies that identify what evidence exists, what evidence is needed, and how the gaps will be closed — before the CER writing begins. It means building PMCF from a documented plan into an operating program that generates clinical data against defined endpoints. It means connecting clinical evaluation to post-market surveillance, risk management, and design controls so that clinical evidence informs and is informed by the broader quality system.

The Transition to Level 3

The organizations that break through the Level 2 plateau share a common realization: the notified body is not asking them to write better documents. It is asking them to do better clinical evaluation. The document improves when the underlying analytical work improves. No amount of template refinement or formatting standardization substitutes for an evaluator who understands the clinical domain, appraises the evidence with methodological rigor, and constructs a benefit-risk argument that reflects genuine clinical judgment.

The MedTechCMM clinical affairs assessment evaluates each dimension of clinical evidence capability independently, recognizing that organizations at Level 2 may have strong procedures in some areas while lacking analytical depth across most. The assessment identifies the specific gap between your procedural maturity and your execution maturity — the distance between what your SOPs describe and what your organization actually produces. Begin at /assessments/clinical-affairs.